Cancer Chemotherapy Center

Innovating safe and effective anti-cancer drugs and treatments

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer More

To identify molecular targets and compounds for cancer therapy

Detail

We discover and develop the novel molecular-targeted drugs by using Cancer Cell Informatics.

Detail

Telomeres, cell immortality and cancer stemness as therapeutic targets

Detail

We promote genome science-driven research for targeted therapy and personalized medicine

Detail

We focus the research between clinical samples and imaging the molecular target

Detail

Akiyoshi, T., Gotoh, O., Tanaka, N., Kiyotani, K., Yamamoto, N., Ueno, M., Fukunaga, Y. and Mori, S.

T-cell complexity and density are associated with sensitivity to neoadjuvant chemoradiotherapy in patients with rectal cancer.
Cancer Immunol. Immunother., in press (2020)
Nozawa, R. S., Yamamoto, T., Takahashi, M., Tachiwana, H., Maruyama, R., Hirota, T. and Saitoh, N.

Nuclear microenvironment in cancer: control through liquid-liquid phase separation.
Cancer Sci., in press (2020)
Nitta, N., Iino, T., Isozaki, A., Yamagishi, M., Kitahama, Y., Sakuma, S., Suzuki, Y., Tezuka, H., Oikawa, M., Arai, F., Asai, T., Deng, D., Fukuzawa, H., Hase, M., Hasunuma, T., Hayakawa, T., Hirai, K., Hiramatsu, K., Hoshino, Y., Inaba, M., Inoue, Y., Ito, T., Karakawa, H., Kasai, Y., Kato, Y., Kobayashi, H., Lei, C., Matsusaka, S., Mikami, H., Nakagawa, A., Numata, k., Ota, T., Sekiya, T., Shiba, K., Shirasaki, Y., Suzuki, N., Tanaka, S., Ueno, S., Watarai, H., Yamano, T., Yazawa, M., Yonamine, Y., Carlo, D. D., Hosokawa, Y., Uemura, S., Sugimura, T., Ozeki, Y. and Goda, K.

Raman image-activated cell sorting.
Naure Communications, 11, 3452 (2020)
Papadopoulos, K. P., Borazanci, E., Shaw, A. T., katayama, R., Shimizu, Y., Zhu, V. W., sun, T. Y., Wakelee, H. A., Madison, R., Schrock, A. B., Senaldi, G., Nakao, N., Hanzawa, H., Tachibana, M., Isoyama, T., Nakamaru, K., Deng, C., Li, M., Fran, F., Zhao, O., Gao, Y., Seto, T., Janne, P. A. and Ou, S. H. I.

US phase 1 first-in-human study of taletrectinib (DS-6051b/AB-106), a ROS1/TRK inhibitor, in patients with advanced solid tumors.
Clin. Cancer Res., in press (2020)
Arai, S., Takeuchi, S., Fukuda, K., Taniguchi, H., Nishiyama, A., Tanimoto, A., Satouchi, M., Yamashita, K., Ohtsubo, K., Nanjo, S., Kumagai, T., Katayama, R., Nishio, M., Zheng, M. M., Wu, Y. L., Nishihara, H., Yamamoto, T., Nakada, M. and Yano, S.

Osimertinib overcomes alectinib resistance caused by amphiregulin in a leptomeningeal carcinomatosis model of ALK-rearranged lung cancer.
J. Thorac. Oncol., 15, 752-765 (2020)